Get notified of page updates

Search Results: Treatment + Prostate Cancer + Hormone Sensitive (0 results)

New Search
Additional Results on Clinicaltrials.gov Treatment + Prostate Cancer + Hormone Sensitive + adt
57 results
Clinical Trial Official Title
NCT06617481 PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
NCT06111781 The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
NCT05915442 Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
NCT06500169 Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors
NCT06039371 Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
NCT06952803 A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06574880 STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
NCT04188535 Serial MRI Scans During Radiation Therapy
NCT05869682 Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
NCT07202247 Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
NCT06922318 The COSMYC Trial (COmbined Suppression of MYC)
NCT04725903 Proton Radiation Therapy for the Treatment of Patients with High Risk Prostate Cancer
NCT06378866 Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
NCT04465500 EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
NCT06150417 MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
NCT06205316 SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
NCT06330805 Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
NCT04705038 Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments
NCT06392295 PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
NCT04787744 Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT06274047 PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
NCT06130995 Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
NCT05790213 Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
NCT07325721 Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer
NCT05361798 T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy
NCT05765500 RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
NCT06563388 Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
NCT04402151 Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT06044857 PSMA PET Response Guided SabR in High Risk Pca
NCT04947254 Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT07210086 Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)
NCT06499870 Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
NCT06244004 FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
NCT07313241 Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
NCT05155046 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
NCT06397703 ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NCT06171269 Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
NCT05939414 An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05053152 Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT06369610 Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
NCT05050084 Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT06636682 FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
NCT07025369 Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
NCT05838716 Vitamin D for Prostate Endocrine Therapy
NCT04423211 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04175431 Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT06305598 Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
NCT06235697 Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT07142967 Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
NCT04775355 Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
NCT05568550 Pembro With Radiation With or Without Olaparib
NCT06111313 The University of Miami Adapt (UAdapt) Trial
NCT05169970 A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
NCT06347705 A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
NCT02997709 Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients
NCT06212583 High-Risk Metachronous Oligometastatic Prostate Cancer Trial
NCT05726292 A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Sponsored By